연구성과로 돌아가기
2025 연구자 정보 (27 / 657)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Liu, Jie (Liu, J) |
Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Oncol, Jinan, Peoples R China |
|
|
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. [JCR상위 2.3] Polygenic Risk Score and Lung Adenocarcinoma Risk Among Never-Smokers by EGFR Mutation Status: A Brief Report |
SCIE | 1.7 |
ONCOLOGY ONCOLOGY;RESPIRATORY SYSTEM |
batel.blechter@nih.gov; | ||
|
Loibl, Sibylle (Loibl, S) |
|
|
[JCR상위 1.7] Trastuzumab deruxtecan (T-DXd) plus pertuzumab (P) vs taxane plus trastuzumab plus pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09. | SCIE | 1.7 | ONCOLOGY | ||||
|
Lv, Fangfang (Lv, FF) |
Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China |
|
|
[JCR상위 1.7] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn; | ||
|
Margolis, David (Margolis, D) |
Brii Biosci Inc, Durham, USA |
|
|
[JCR상위 1.7] Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | jia_jd@ccmu.edu.cn; | ||
|
Meeks, Joshua J. (Meeks, JJ) |
|
|
[JCR상위 1.7] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Moon, Yong Wha (Moon, YW) |
|
|
[JCR상위 1.7] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Nam, Joon Yeul (Nam, JY) |
Seoul HIM Clin, Seoul, South Korea |
|
0000-0003-4471-5529 Nam, Joon Yeul |
[JCR상위 1.7] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com; | ||
|
Nishiyama, Hiroyuki (Nishiyama, H) |
|
|
[JCR상위 1.7] Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA. | SCIE | 1.7 | ONCOLOGY | ||||
|
Park, Ho Yong (Park, HY) |
Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea |
|
|
[JCR상위 1.7] Real-time AI-based computer-aided detection/diagnosis (AI-CAD) for breast ultrasound: A prospective, multicenter, multinational study. [JCR상위 91.3] Clinical Application of Artificial Intelligence in Breast Ultrasound [JCR상위 2.5] Body mass index and progesterone receptor in postmenopausal ER-positive/HER2-negative breast cancer: A nation-wide study in Korean breast cancer society and the multi-institutional cohort [JCR상위 1.7] Role of EMP2 in triple-negative breast cancer. [JCR상위 1.7] Predicting high-risk group according to Oncotype DX recurrence score using dynamic contrast-enhanced breast MR with temporal radiomic features. |
SCIE ESCI |
1.7 |
ONCOLOGY RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING OBSTETRICS & GYNECOLOGY;ONCOLOGY |
greenoaktree9@gmail.com; asg2004@yuhs.ac; |
||
|
Park, In Hae (Park, IH) |
|
|
[JCR상위 1.7] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY | ||||
|
Park, Jeayeon (Park, J) |
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea |
|
|
[JCR상위 1.7] AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | pindra@empal.com; | ||
|
Park, Jee-Young Nora (Park, JYN) |
|
|
[JCR상위 1.7] Role of EMP2 in triple-negative breast cancer. | SCIE | 1.7 | ONCOLOGY | ||||
|
Park, Ji-young (Park, JY) |
|
|
[JCR상위 1.7] Role of EMP2 in triple-negative breast cancer. | SCIE | 1.7 | ONCOLOGY | ||||
|
Park, Jung Gil (Park, JG) |
Yeungnam Univ, Coll Med, Daegu, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Daegu, South Korea |
|
|
[JCR상위 1.7] Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | wonshiri@yahoo.com; | ||
|
Park, Kyonghwa (Park, K) |
|
|
[JCR상위 1.7] Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial. | SCIE | 1.7 | ONCOLOGY |
페이지 이동: